Brief: Auris Medical Announces Positive Top-Line Data From Am-201 Phase 1B Study In Antipsychotic-Induced Weight Gain

Altamira Therapeutics

26/05/2020 13:42

May 26 (Reuters) - Auris Medical Holding Ltd  EARS.O :
    * AURIS MEDICAL ANNOUNCES POSITIVE TOP-LINE DATA FROM AM-201
PHASE
1B STUDY IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN AND PROVIDES
UPDATE ON TRAVERS PHASE 2 STUDY
    * AURIS MEDICAL - ADMINISTRATION OF INTRANASAL BETAHISTINE
30 MG
SHOWS STATISTICALLY SIGNIFICANT REDUCTION IN OLANZAPINE-INDUCED
WEIGHT GAIN
    * AURIS MEDICAL -  TREATMENT FROM AM-201 PHASE 1B STUDY WELL
TOLERATED AND SAFE WITH NO ADVERSE EFFECTS
    * AURIS MEDICAL - ENROLLMENT INTO PHASE 2 TRAVERS TRIAL WITH
AM-125 RESUMED FOLLOWING BREAK DUE TO COVID-19 PANDEMIC

Source text for Eikon:  ID:nGNX3zdDRm 
Further company coverage:  EARS.O 

 ((Reuters.Briefs@thomsonreuters.com;))